Status and phase
Conditions
Treatments
About
This Phase 1/2, open-label, dose-finding study is intended to evaluate the safety and tolerability, PK, PD, and efficacy of INCB000928 administered as monotherapy in participants with MDS or MM who are transfusion-dependent or present with symptomatic anemia.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
For MDS participants:
For MM participants:
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
22 participants in 1 patient group
Loading...
Central trial contact
Incyte Corporation Call Center (US); Incyte Corporation Call Center (ex-US)
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal